Arcutis Biotherapeutics ARQT
Revenue per employee
354 employees as of 2025/FY (+3.5% YoY). Revenue per employee is total revenue divided by headcount — a rough productivity gauge, not a per-worker pay figure.
Management team
Background
Todd Franklin Watanabe has served as our President and Chief Executive Officer, and as a member of our Board of Directors, since April 2017. Prior to joining Arcutis, he served as co-founder and Chief Operating Officer of Kanan Therapeutics, Inc., a cardiovascular drug development company from December 2015 to February 2018, and before that, he served as Vice President of Strategy and Corporate Development at Kythera Biopharmaceuticals Inc. from October 2013 to November 2015. Mr. Watanabe was an executive at Amgen Inc. from 2005 to 2013, where he was involved in the development of Repatha for hyperlipidemia and Aimovig for migraine, and worked on the U.S. marketing of Enbrel in both dermatology and rheumatology. Previously, he was an executive with Eli Lilly and Company, and an official in the U.S. Government. He was also a commissioned officer in the U.S. Navy Reserves for 25 years. Mr. Watanabe is also the Vice Chairperson of the Biotechnology Innovation Organization (BIO), and co-chairs that board's advocacy and nominations, governance & membership committees. Mr. Watanabe received his M.A. in National Security Studies, and his B.A. in International Relations, both from Georgetown University.
Background
Patrick E. Burnett, M.D., Ph.D. has served as our Executive Vice President and Chief Medical Officer since December 2024 and prior as Senior Vice President and Chief Medical Officer since August 2020. Prior to that Dr. Burnett was the Chief Medical Officer at Verrica Pharmaceuticals since April 2018. Prior to that, Dr. Burnett was at Sun Pharmaceuticals where he was Associate Vice President of Clinical Development from September 2015 to March 2018, with oversight of the dermatology and rheumatology pipeline. Prior to Sun Pharmaceuticals, Dr. Burnett was at Novartis from 2010 to August 2015, most recently as Global Program Medical Director. He is a board certified dermatologist and was a member of the medical faculty at Vanderbilt University Medical Center as an Assistant Professor of Dermatology from 2004 to 2010. Dr. Burnett holds an M.D. and Ph.D. in neuroscience from Johns Hopkins School of Medicine and a B.S. in Biology and Biochemistry from the University of Iowa.
Background
Masaru Matsuda, JD has served as our Executive Vice President, Chief Legal Officer and Corporate Secretary since March 2026 and prior as Senior Vice President, General Counsel and Corporate Secretary since January 2022. Mr. Matsuda most recently served as Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary at Halozyme Therapeutics, Inc., where he worked from August 2018 through December 2021. Prior to Halozyme, Mr. Matsuda worked at Amgen for 18 years in positions of increasing responsibility with his last role serving as Vice President, Law, Global Commercial Operations, where he was responsible for strategic commercial legal support to the US Commercial Operations organization, as well as Medical Affairs, Compliance, Global Value, Access & Policy, Global Marketing, and Biosimilars divisions. Mr. Matsuda received a B.S. in Business Administration with a dual emphasis in Corporate Finance and International Finance from the University of Southern California, and J.D. from University of California College of the Law, San Francisco.
Background
On April 10, 2025, Arcutis Biotherapeutics, Inc. announced the appointment of Latha Vairavan, the Company's current Vice President, Finance and Corporate Controller, as the Company's Senior Vice President and Chief Financial Officer, effective immediately on May 15, 2025. Ms. Vairavan, age 47, has served as Vice President, Finance and Corporate Controller for the Company since August 2024, where she has been responsible for overseeing daily accounting operations, ensuring compliance with financial, accounting, and income tax regulations, all investor relations activities, and overseeing financial planning and analysis. She joined the Company in March 2020 and previously held positions as Vice President of Finance and Investor Relations and Executive Director, Financial Planning and Analysis. Prior to that, Ms. Vairavan worked at Amgen Inc., a publicly traded biopharmaceutical company, for 12 years, where she held various roles of increasing responsibility within the finance organization, culminating as Finance Director for US Value and Access. Ms. Vairavan started her career as a financial consultant working for accounting firms KPMG and Arthur Andersen. She holds a B.S. in Business Administration, Finance from the University of Southern California and is a licensed CPA in California.
Background
Amit D. Munshi has served as a member of our Board of Directors and as the Chair of the Compensation Committee of the Board since December 2025. Since February 2026, Mr. Munshi has served as Interim Chief Executive Officer of Sensorion SA, a clinical-stage biotechnology company, where he has also been a board member since April 2025. Mr. Munshi was previously the President, Chief Executive Officer and as a board member of Orna Therapeutics, Inc., a biotechnology company, from May 2024 to April 2025. Prior to this, Mr. Munshi served as the President, Chief Executive Officer and as a board member of ReNAgade Therapeutics, Inc., an RNA therapeutics company, from May 2023 until its acquisition by Orna Therapeutics, Inc. in May 2024. Mr. Munshi previously served as the President and Chief Executive Officer of Arena Pharmaceuticals Inc., a then-publicly traded biopharmaceutical company, from May 2016 to March 2022, and a member of its Board of Directors from June 2016 until its acquisition by Pfizer in March 2022. Mr. Munshi was previously the Chief Executive Officer of Epirus Biopharmaceuticals, which filed for bankruptcy on July 25, 2016, and was previously Chief Executive Officer of Percivia LLC (acquired by Johnson & Johnson) and Chief Business Officer and co-founder of Kythera Biopharmaceuticals Inc. (acquired by Allergan). Mr. Munshi serves as a board member for a number of public biotechnology and pharmaceutical companies, including for Inhibikase Therapeutics, Inc. since October 2024, Zura Bio Limited and its predecessor since November 2022, and Galecto since May 2020. Mr. Munshi also previously served as a board member of Pulmatrix Inc., a publicly traded biopharmaceutical company from June 2017 until March 2021. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker School of Management at Claremont Graduate University.
Background
Keith R. Leonard, Jr. has served as a member of our Board of Directors since September 2021 and has served as the Chair of our Board of Directors since November 2024. Mr. Leonard was previously chairman of the board of Unity Biotechnology Inc. where he served as chief executive officer from 2016 to 2020, and currently serves on the board of robotic surgery pioneer Intuitive Surgical. Previously, Mr. Leonard served as the chief executive officer of Kythera Biopharmaceuticals from its founding in 2005 to its acquisition by Allergan plc in 2015. Before Kythera, Mr. Leonard spent 13 years at Amgen, ultimately as senior vice president and general manager of Amgen Europe, where he ran all commercial operations in 28 countries. Prior to that position, Mr. Leonard ran Amgen's manufacturing operations in Europe, established Amgen's presence in inflammation, served as head of information management, and had leadership roles in sales and marketing, engineering, operations, and finance. Mr. Leonard previously served as an independent director of Sanifit Laboratories SA (a privately held clinical-stage biopharmaceutical company), Sienna Biopharmaceuticals, Inc., Anacor Pharmaceuticals, Inc., Affymax, Inc., and ARYx Therapeutics, and was a venture partner with ARCH Venture Partners. Mr. Leonard began his career as an officer in the Civil Engineer Corps of the U.S. Navy. He holds a Master of Business Administration from the Anderson School of Management, University of California, Los Angeles, a Master of Science in mechanical engineering from University of California, Berkeley, a Bachelor of Arts in history from University of Maryland, College Park, and a Bachelor of Science in engineering from University of California, Los Angeles.
Background
Sue-Jean Lin has served as a member of our Board of Directors since June 2021 and has served as the Chair of the Audit Committee since September 2022. Ms. Lin retired in March 2025 from Alcon, where she held the position of Senior Vice President, Chief Information and Transformation Officer, and was a member of the Executive Committee. During her tenure at Alcon, she built and led a world-class global information technology organization and contributed to company's success after its spin-off from Novartis in 2019. From 2016 to 2018, she was a member of the Hill-Rom executive leadership team, serving in the capacity of senior vice president and chief information officer. In this role, she was instrumental in developing an innovative remote care in hospital acute care settings that enhanced patient engagement and improved the effectiveness of healthcare professionals. From 1989 to 2015, she held multiple roles at Allergan (prior to it being acquired by AbbVie Inc.), including as the senior vice president and chief information officer, and as the regional chief financial officer, VP of finance and controller, for Europe, Middle East, Africa, and Asia Pacific. Since June 2025, Ms. Lin has served on the board of Stevanato Group S.p.A., a public company specializing in drug containment and delivery solutions. Ms. Lin holds a bachelor's degree in accounting and a master's degree in business administration from the University of Nevada, Reno. She also holds a certificate in Effective AI Oversight from Carnegie Mellon University's Heinz College of Information Systems and Public Policy and the National Association of Corporate Directors, as well as a CERT Certificate in Cyber-Risk Oversight from Carnegie Mellon University's Software Engineering Institute, Ridge Global and the National Association of Corporate Directors.
Background
Terrie Curran has served as a member of our Board of Directors since November 2020 and has served as the Chair of the Nominating and Corporate Governance Committee since 2021. Ms. Curran served as the Chief Executive Officer and President of Phathom Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal diseases, from December 2019 to March 2025, and served as a member of its Board of Directors since August 2019 to March 2025. From November 2016 to 2023, Ms. Curran served as a member of the Board of Directors of Myovant Sciences Ltd., a clinical-stage biopharmaceutical company with a focus on treatments for women suffering from uterine fibroids, endometriosis and infertility and men suffering from prostate cancer. Ms. Curran previously served as the President, Global Inflammation and Immunology (I&I) Franchise at Celgene Corporation and a member of its Executive Committee from April 2017 until November 2019. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful launch of OTEZLA, before becoming Head of Worldwide Markets. Prior to joining Celgene, she served as Senior Vice President and General Manager - Global Women's Health at Merck & Co. Before joining Merck, Ms. Curran held a number of Country General Manager positions at Schering-Plough and Pharmacia across Europe and Asia Pacific. She previously served on the board of H. Lundbeck A/S, a global pharmaceutical company. Ms. Curran holds a Graduate Diploma of Marketing and a Bachelor of Applied Science (B.A.S.) from the University of Technology, Sydney.
Background
Halley E. Gilbert has served as a member of our Board of Directors since May 2020. Ms. Gilbert is currently the Chief Operating Officer and Chief Legal Officer of Tubulis GmbH, an antibody drug conjugate oncology company, a position she has held since September 2025. Prior to Tubulis, Ms. Gilbert was Chief Legal Officer of CARGO Therapeutics, a cell therapy company focused on oncology indications until it was acquired by Concentra Biosciences in August 2025. From August 2021 through April 2022, Ms. Gilbert served as Chief Legal Officer of NeoGenomics Laboratories, a cancer diagnostics company. From July 2020 to August 2021, Ms. Gilbert served as Chief Operating Officer of Invivyd, Inc. (formerly, Adagio Therapeutics), a clinical stage company developing antibodies for infectious diseases. Prior to Invivyd, Ms. Gilbert held various roles at Ironwood Pharmaceuticals from February 2008 through February 2020, including Senior Vice President for Corporate Development, Chief Administrative Officer, and Chief Legal Officer. Prior to joining Ironwood Pharmaceuticals, Ms. Gilbert was Vice President, Deputy General Counsel at Cubist Pharmaceuticals, Inc. and previously served as a corporate counsel at Genzyme Corp., prior to its acquisition by Sanofi. She began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law. Ms. Gilbert currently serves on the Board of Directors, including as chair of the nominating and corporate governance committee and a member of the audit committee, of each of Vaxcyte, Inc., a biopharmaceutical company developing vaccines for infectious disease targets, and CytomX Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutic cancer treatments. Ms. Gilbert previously served on the Board of Directors of Dermira, Inc. (acquired by Eli Lilly and Company), a commercial-stage company focused on medical dermatology, and Achaogen, Inc. (acquired by Cipla), a commercial-stage biopharmaceutical company that developed novel antibacterial therapies. Ms. Gilbert holds a B.A. in Political Science from Tufts University and J.D. from Northwestern University School of Law.
Background
Neha Krishnamohan has served as a member of our Board of Directors since September 2022. Ms. Krishnamohan is currently the Chief Financial Officer and Chief Business Officer at Latigo Biotherapeutics, a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain at its source. Previously, Ms. Krishnamohan was the Chief Financial Officer and Executive Vice President, Corporate Development at Artiva Biotherapeutics, Inc., an off-the-shell NK cell therapy company focused on autoimmune and oncology indications from April 2024 to December 2025. Ms. Krishnamohan served as Chief Financial Officer and Executive Vice President, Corporate Development at Kinnate Biopharma Inc., a publicly traded biopharmaceutical company from June 2021 until its acquisition by XOMA Corporation in April 2024. Prior to joining Kinnate, Ms. Krishnamohan was with Goldman Sachs where she held various roles since July 2008, most recently as Vice President in the Healthcare Investment Banking Group. During Ms. Krishnamohan's tenure at Goldman Sachs, she advised a variety of biopharmaceutical company Board of Directors and management teams on a broad range of strategic financial matters, and executing financings and leading M&A transactions. Ms. Krishnamohan holds a B.S.E. with a double major in Biomedical Engineering and Economics from Duke University.
Background
Patrick J. Heron has been a member of our Board of Directors since April 2016. Since September 1999, Mr. Heron has been a managing general partner with Frazier Life Sciences, where he has been active in company formations and initial investments in various biotechnology companies, including Marcadia Biotech Inc., Calixa Therapeutics, Inc. and VentiRx Pharmaceuticals, Inc. He also led Frazier's involvement in MedPointe Inc. Prior to joining Frazier, Mr. Heron helped develop McKinsey & Company's west coast biotechnology consulting practice. In addition, Mr. Heron currently serves on the Board of Directors of the following public companies: MBX Biosciences, Inc. and Mirum Pharmaceuticals, Inc. He also previously served on the Board of Directors of other public companies including Vaxcyte, Inc. (2017 to 2021), Passage Bio, Inc. (2018 to 2021) and Imago Biosciences, Inc. (2014 to 2022). In addition, Mr. Heron currently serves on the Board of Directors of several private companies: Alpha-9 Theranostics, Inc., Alceptor Therapeutics, Inc., Bluewater Biosciences, Inc. and Tubulis GmbH. Mr. Heron received a B.A. in Political Science from the University of North Carolina at Chapel Hill and an M.B.A. from Harvard Business School.
Background
Howard G. Welgus, M.D. has served as a member of our Board of Directors since August 2020. Dr. Welgus served as our Chief Medical Officer from April 2017 to July 2020. From February 2016 to June 2018, Dr. Welgus served as the Chief Medical Officer at Verrica Pharmaceuticals Inc. Prior to joining Verrica, Dr. Welgus served as the Chief Medical Officer at Thesan Pharmaceuticals Inc. from September 2012 to November 2016 and served as the Chief Medical Officer at Nycomed US Inc. from May 2009 to November 2010. From 1999 to 2009, he served as the Vice President and head of the Dermatology and Inflammation therapeutic areas in Discovery at Pfizer Inc. in Ann Arbor, MI. Prior to joining the private sector, Dr. Welgus was a faculty member at Washington University for 17 years. Dr. Welgus is a board-certified dermatologist and received a M.D. from Washington University School of Medicine in St. Louis and a B.A. in Biology from Rice University.
Background
Mr. Robert Scott, Robert Scott, M.D., age 73, has served in various leadership positions in the global pharmaceuticals industry for several decades. Dr. Scott previously served as Chief Medical Officer and Head of Development of AbbVie Inc., a publicly traded global biopharmaceutical company, from April 2016 until his retirement in April 2020. Prior to AbbVie Inc., Dr. Scott served as Vice President, Global Development and Therapeutic Area Head at Amgen Inc., a publicly traded global biopharmaceutical company, from November 2010 to March 2016. In that role, he led the Cardiovascular, Metabolic, Nephrology, Neuroscience, Bone and Inflammation Therapeutic Areas and was Head of the Amgen Development Design Center. Before Amgen Inc., Dr. Scott served as Chief Medical Officer and Head of Development of Cerenis Therapeutics, a then-privately held pharmaceutical company, from January 2008 to May 2010. He also previously served as Executive Vice President, Research and Development and Chief Medical Officer of AtheroGenics, Inc., a biopharmaceutical company, from August 2002 to September 2007. Prior to AtheroGenics, Inc., Dr. Scott held various positions at Pfizer Inc. from 1992 to 2002, most recently as Vice President, Worldwide Therapeutic Head of the Cardiovascular and Metabolic Group. He began his career in the pharmaceutical industry as a Medical Advisor at Janssen, an affiliate of Johnson & Johnson, from 1987 to 1989. From January 2012 to December 2016, Dr. Scott served as the non-voting industry representative on the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee. Dr. Scott currently serves as a member of the boards of directors of Confo Therapeutics, Draupnir Bio, Oncospherix and Variant Bio, each a private biotechnology company. He previously served as a member of the boards of directors of Windtree Therapeutics, Inc., a publicly traded biotechnology company, from February 2021 to September 2024, Redx Pharma plc, a formerly publicly traded pharmaceutical company that was listed on the London Stock Exchange, from January 2024 to December 2024, and ArisGlobal, a private life sciences software company, from June 2020 to October 2024. Dr. Scott holds a B.Sc. in Microbiology and Biochemistry and an M.B.Ch.B. in Medicine from the University of Cape Town and a Diploma in Obstetrics from the College of Medicine of South Africa.
Background
The Company has appointed Robert Lisicki as interim executive vice president, starting August 17, 2026, and as interim chief commercial officer, effective on August 21, 2026. Mr. Lisicki, 59, most recently served as chief executive officer and a director at Zura Bio Limited from April 2024 to January 2026, and was previously their president and chief operating officer from January 2024. Mr. Lisicki is an experienced executive leader with a career spanning over 30 years in the biopharmaceutical industry. Mr. Lisicki has served on the board of Cadrenal Therapeutics, Inc. since July 2023. He previously served as the chief executive officer and a member of the board of directors of InCarda Therapeutics, Inc. from October 2022 to April 2023, where he remained as a consultant until June 2023. Mr. Lisicki previously served as the chief commercial officer at Arena Pharmaceuticals, Inc. from October 2018 until its acquisition by Pfizer in March 2022. At Arena Pharmaceuticals, Inc., Mr. Lisicki built the company's global commercial infrastructure and contributed to its mergers and acquisitions activities totaling nearly $8.0 billion. Prior to Arena Pharmaceuticals, Inc., Mr. Lisicki served as vice president and general manager of inflammation and cardiovascular at Regeneron Pharmaceuticals, Inc. In this dual role, he led both commercial and developmental initiatives. His career also includes serving as a member of the board of CorHepta Therapeutics Inc. from May 2023 to January 2025 and Adiso Therapeutics, Inc. from October 2023 to August 2024, and in senior leadership roles as chief customer officer of Daiichi Sankyo, Inc. from August 2014 to April 2018, and in roles of increasing responsibility including vice president of Amgen Inc. from July 2005 to August 2014, with his initial experience in sales and marketing at The Janssen Pharmaceutical Companies of Johnson & Johnson from March 1995 to June 2005. He holds a Bachelor of Science degree in Finance and Economics from the State University of New York, Albany, New York.
Background
On July 15, 2026, the Board of Directors of Arcutis Biotherapeutics, Inc. increased the authorized number of directors on the Board from nine to ten directors and appointed Mr. Christopher Peetz as a new member of the Board. Mr. Peetz is a co-founder of Mirum Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, where he has served as Chief Executive Officer since March 2019 and as President from November 2018 to January 2024. Prior to Mirum Pharmaceuticals, Inc., Mr. Peetz served as Chief Executive Officer of Flashlight Therapeutics, Inc., a biotechnology company, from May 2017 to May 2019. He also previously served as Chief Financial Officer and head of corporate development at Tobira Therapeutics, Inc., a publicly-traded biotechnology company acquired by Allergan plc. in November 2016, from May 2014 to December 2016. Prior to joining Tobira Therapeutics, Inc, Mr. Peetz served as Vice President, Finance and Corporate Development of Jennerex Biotherapeutics, Inc., a biopharmaceutical company. Prior to Jennerex, Mr. Peetz held various positions at Onyx Pharmaceuticals, Inc. (now Amgen Inc.), including corporate strategy, marketing, product lifecycle management, and financial planning. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He also served as a member of the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company, from April 2018 until its sale to Vertex in May 2024. Mr. Peetz has been an entrepreneur-in-residence at Frazier Life Sciences since May 2017. Mr. Peetz received an M.B.A. from Stanford Graduate School of Business and a B.S.B.A. in finance, international business, and French from Washington University in St. Louis.
From SEC filings, via Futu. Compensation is total reported pay for the most recent fiscal year on file, not base salary alone.
No comments yet — be the first to weigh in on ARQT.
Sign in to join the discussion.